InvaGen Pharmaceuticals, a subsidiary of drug major Cipla, received the final approval from the US Food and Drug Administration for Pregabalin capsules, the company announced this Monday. The drug has been approved for the following dosages: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg. This drug has been indicated for the management of neuropathic pain, which is related to many ailments.
These capsules are to be used for neuropathic pain management by people suffering from numerous conditions, such as postherpetic neuralgia, diabetic peripheral neuropathy, spinal cord injury, partial onset seizures in patients 17 years of age and older, and fibromyalgia. As mentioned by Cipla, the approved product is a generic equivalent of Pfizer’s Lyrica. Citing IQVIA’s data, Cipla said that in the year that ended in March 2019, a market size of $5.4 billion was attained by Lyrica.